Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue: +192.6%
EPS: +55.8%
Free cash flow: +60.5%
Total debt: +4.21%

Quarter to September 2026, against a year earlier

74.06 0.21 −0.28%

Follow BBIO

Alert me

Market cap: $14.5B
P/E: 0.0×
Fwd P/E: −27.5×
Dividend yield: —
F-score: 3/9
Altman Z: −3.45
Beneish M: 8.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BridgeBio Pharma, Inc. 8-K filed Jan 21, 2026

Period ended Jan 14, 2026 · Filed Jan 21, 2026 · accepted 4:07 PM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov

BridgeBio Pharma, Inc. 8-K filed Jan 21, 2026

Stockrow Weekly